• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Failure of ACAT inhibition to retard atherosclerosis.

作者信息

Fazio Sergio, Linton MacRae

出版信息

N Engl J Med. 2006 Mar 23;354(12):1307-9. doi: 10.1056/NEJMe068012.

DOI:10.1056/NEJMe068012
PMID:16554534
Abstract
摘要

相似文献

1
Failure of ACAT inhibition to retard atherosclerosis.
N Engl J Med. 2006 Mar 23;354(12):1307-9. doi: 10.1056/NEJMe068012.
2
Effect of ACAT inhibition on the progression of coronary atherosclerosis.
N Engl J Med. 2006 Mar 23;354(12):1253-63. doi: 10.1056/NEJMoa054699.
3
Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study.新型抗动脉粥样硬化疗法的血管内超声评估：酰基辅酶A：胆固醇酰基转移酶血管内动脉粥样硬化治疗评估（ACTIVATE）研究的原理与设计
Am Heart J. 2006 Jul;152(1):67-74. doi: 10.1016/j.ahj.2005.10.025.
4
ACAT inhibition and the progression of coronary atherosclerosis.
N Engl J Med. 2006 Jun 15;354(24):2616-7; author reply 2616-7. doi: 10.1056/NEJMc061094.
5
Carotid atherosclerosis progression and ACAT inhibition.
JAMA. 2009 Jul 15;302(3):255; author reply 256-7. doi: 10.1001/jama.2009.1000.
6
[New agents against atherosclerosis tested. Alarming findings, ACAT inhibitors seem to have proatherogenic effects].[新型抗动脉粥样硬化药物的测试。令人担忧的发现，酰基辅酶A胆固醇酰基转移酶（ACAT）抑制剂似乎具有促动脉粥样硬化作用]
Lakartidningen. 2006;103(43):3270.
7
Can we cause regression of coronary atherosclerosis?我们能使冠状动脉粥样硬化消退吗？
Am J Med Sci. 2008 May;335(5):368-74. doi: 10.1097/MAJ.0b013e31815c3b32.
8
Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.酰基辅酶A：胆固醇酰基转移酶抑制剂阿伐西丁对人动脉粥样硬化病变的影响。
Circulation. 2004 Nov 23;110(21):3372-7. doi: 10.1161/01.CIR.0000147777.12010.EF. Epub 2004 Nov 8.
9
Atherosclerosis drug fails to meet Phase III trial end point.动脉粥样硬化药物未达到III期试验终点。
Nat Rev Drug Discov. 2009 May;8(5):348. doi: 10.1038/nrd2879.
10
ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.
Atherosclerosis. 2007 Feb;190(2):239-47. doi: 10.1016/j.atherosclerosis.2006.03.007. Epub 2006 Apr 19.

引用本文的文献

1
Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation.基于深度对接、药效团建模和分子动力学模拟的组合策略发现选择性 ACAT2 拮抗剂。
J Enzyme Inhib Med Chem. 2024 Dec;39(1):2403736. doi: 10.1080/14756366.2024.2403736. Epub 2024 Sep 24.
2
Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy.靶向固醇O-酰基转移酶1以破坏胆固醇代谢用于癌症治疗。
Front Oncol. 2023 Jun 20;13:1197502. doi: 10.3389/fonc.2023.1197502. eCollection 2023.
3
Short-Term Acyl-CoA:Cholesterol Acyltransferase Inhibition, Combined with Apoprotein A1 Overexpression, Promotes Atherosclerosis Inflammation Resolution in Mice.
短期酰基辅酶 A：胆固醇酰基转移酶抑制作用，联合载脂蛋白 A1 过表达，促进小鼠动脉粥样硬化炎症消退。
Mol Pharmacol. 2021 Mar;99(3):175-183. doi: 10.1124/molpharm.120.000108. Epub 2020 Dec 31.
4
Synthesis and Evaluation of C- and F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents.作为巨噬细胞泡沫细胞成像剂的C和F标记的SOAT1抑制剂的合成与评价
ACS Med Chem Lett. 2020 Apr 30;11(6):1299-1304. doi: 10.1021/acsmedchemlett.0c00127. eCollection 2020 Jun 11.
5
Identification of potential ACAT-2 selective inhibitors using pharmacophore, SVM and SVR from Chinese herbs.利用药效团、支持向量机和支持向量回归从中药中鉴定潜在的ACAT-2选择性抑制剂。
Mol Divers. 2016 Nov;20(4):933-944. doi: 10.1007/s11030-016-9684-9. Epub 2016 Jun 21.
6
New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models.新型吡喃并吡喃烯A衍生物，高度选择性的SOAT2抑制剂，可改善动脉粥样硬化小鼠模型中的高胆固醇血症和动脉粥样硬化。
J Pharmacol Exp Ther. 2015 Nov;355(2):299-307. doi: 10.1124/jpet.115.227348. Epub 2015 Sep 3.
7
Modulation of triglyceride and cholesterol ester synthesis impairs assembly of infectious hepatitis C virus.甘油三酯和胆固醇酯合成的调节会损害丙型肝炎病毒的组装。
J Biol Chem. 2014 Aug 1;289(31):21276-88. doi: 10.1074/jbc.M114.582999. Epub 2014 Jun 10.
8
Hepatic ACAT2 knock down increases ABCA1 and modifies HDL metabolism in mice.肝脏中ACAT2基因敲低可增加ABCA1表达并改变小鼠的高密度脂蛋白代谢。
PLoS One. 2014 Apr 2;9(4):e93552. doi: 10.1371/journal.pone.0093552. eCollection 2014.
9
Novel lipid droplet-associated serine hydrolase regulates macrophage cholesterol mobilization.新型脂滴相关丝氨酸水解酶调节巨噬细胞胆固醇动员。
Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):386-96. doi: 10.1161/ATVBAHA.113.302448. Epub 2013 Dec 19.
10
ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity.ACAT 抑制可减少已存在的、进展中的动脉粥样硬化小鼠病变的进展，而无斑块或全身毒性。
Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):4-12. doi: 10.1161/ATVBAHA.112.252056. Epub 2012 Nov 8.